Tagraxofusp + Chemotherapy for Acute Lymphoblastic Leukemia
Trial Summary
What is the purpose of this trial?
This phase Ib/II trial studies the effects of tagraxofusp and low-intensity chemotherapy in treating patients with CD123 positive acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Tagraxofusp consists of human interleukin 3 (IL3) linked to a toxic agent called DT388. IL3 attaches to IL3 receptor positive cancer cells in a targeted way and delivers DT388 to kill them. Chemotherapy drugs, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving tagraxofusp with chemotherapy may help control CD123 positive relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma.
Research Team
Nicholas Short
Principal Investigator
M.D. Anderson Cancer Center
Eligibility Criteria
Adults aged 18-70 with CD123 positive relapsed or refractory acute lymphoblastic leukemia or lymphoblastic lymphoma can join. They must have certain normal blood test results, no serious heart, liver, lung diseases, HIV, hepatitis B/C and agree to use effective birth control. Pregnant women and those with other life-threatening cancers cannot participate.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Dexamethasone
- Tagraxofusp
Tagraxofusp is already approved in United States, European Union for the following indications:
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor